Resources

Resources

Hear from NextGen's expert advisors with insights and advice on the evolving COVID-19 pandemic and beyond.

Read Blog

The financial and clinical challenges you face now are evolving rapidly. Here are resources, solutions, and ideas we think will help.

Read Now

Industry news

NextGen Advisors Podcast: FDA Approves Alzheimer’s Treatment, Controversy Ensues

By NextGen Healthcare

Subscribe to receive email updates as new information becomes available.   Subscribe now

Blog Home    NextGen Advisors Podcast: FDA Approves Alzheimer’s Treatment, Controversy Ensues
Showing of results

Alzheimer’s disease affects 6.2 million Americans each year so the recent approval by the FDA of Biogen’s drug Aduhelm was met with hope by many patients and their advocates. The approval process used by the FDA, the efficacy data compiled to date, and the expected annual cost of the drug have created a swirl of controversy around the decision. In this episode of the NextGen Advisors podcast, Graham Brown and Dr. Betty Rabinowitz discuss the drug’s approval and the concerns, hopes and implications it has raised.


NextGen Healthcare

NextGen Healthcare is a solutions provider whose comprehensive, integrated technology and services platform supports ambulatory and specialty practices of all sizes.

Get in touch with NextGen Healthcare

The financial and clinical challenges you face now are evolving rapidly. Here are resources, solutions, and ideas we think will help.

Read Now

Follow us